Cadrenal Therapeutics, INC 8-K filings

Cadrenal Therapeutics is restructuring its clinical portfolio into a Cardiac Acute Critical Care Franchise and initiating a process to find strategic partners for its late-stage assets.

Cadrenal Therapeutics, Inc. has entered into a separation agreement with its Chief Medical Officer, James J. Ferguson III, who will resign effective July 31, 2026.

Cadrenal Therapeutics, Inc. reported the resignation of its Chief Medical Officer, James J. Ferguson III, effective July 31, 2026, and is currently seeking a replacement.

Cadrenal Therapeutics announced a private placement raising approximately $3 million through the sale of pre-funded warrants and common warrants, with net proceeds intended for working capital.

Cadrenal Therapeutics, Inc. has appointed John P. Sharp as Interim Chief Financial Officer and entered into a new Scope of Work with Lohman & Associates, Inc. for financial consulting services.

Cadrenal Therapeutics announced plans to seek FDA Rare Pediatric Disease Designation for tecarfarin in treating pediatric Kawasaki disease patients with coronary artery aneurysms, alongside a dual-track portfolio strategy.

Cadrenal Therapeutics announced the departure of its Chief Financial Officer, Matthew K. Szot, with CEO Quang X. Pham assuming interim CFO duties.

Cadrenal Therapeutics reported Q1 2026 financial results and provided a significant update on its CAD-1005 program, confirming a clear path for a pivotal Phase 3 trial in heparin-induced thrombocytopenia (HIT) following FDA guidance.

Cadrenal Therapeutics announced a successful End-of-Phase 2 meeting with the FDA, paving the way for a pivotal Phase 3 trial of its investigational drug CAD-1005 for Heparin-Induced Thrombocytopenia (HIT).

Cadrenal Therapeutics, Inc. announced a warrant inducement agreement generating $2.5 million in gross proceeds and issuing new warrants to a holder.

Cadrenal Therapeutics reported its full-year 2025 financial results and provided a corporate update highlighting progress on its CAD-1005 program for heparin-induced thrombocytopenia (HIT), including positive Phase 2 data and a successful End-of-Phase 2 FDA meeting.

Cadrenal Therapeutics announced preclinical research demonstrating its CAD-1005 inhibitor's potential to target inflammatory consequences of obesity and Type 2 diabetes.

Cadrenal Therapeutics announced encouraging Phase 2 results for CAD-1005 in heparin-induced thrombocytopenia (HIT), showing a 25% absolute reduction in thrombotic events despite missing its primary endpoint.

Cadrenal Therapeutics, Inc. announced an update to its At-the-Market offering program, making available up to an additional $1.77 million in common stock.

Cadrenal Therapeutics, Inc. announced a registered direct offering and concurrent private placement to raise approximately $2.2 million for working capital.

Cadrenal Therapeutics has acquired VLX-1005, a first-in-class Phase 2 12-LOX inhibitor for Heparin-Induced Thrombocytopenia (HIT), significantly strengthening its anticoagulation pipeline.

Cadrenal Therapeutics, Inc. announced the appointment of Dr. Lee Scott Golden, a seasoned biopharmaceutical executive, to its Board of Directors, effective immediately.

Cadrenal Therapeutics, Inc. filed a prospectus supplement to offer and sell up to an additional $3.4 million of common stock through its existing at-the-market program.

Cadrenal Therapeutics reported third quarter 2025 financial results, highlighted progress in tecarfarin's clinical development, and announced the acquisition of frunexian.

Cadrenal Therapeutics stockholders elected Steven Zelenkofske as a Class III director and ratified WithumSmith+Brown, P.C. as their independent auditor at the 2025 annual meeting.

Cadrenal Therapeutics significantly expands its anticoagulation pipeline by acquiring eXIthera Pharmaceuticals' Factor XIa inhibitor assets, including Phase 2-ready Frunexian.

Cadrenal Therapeutics reported Q2 2025 financial results and announced strategic plans to initiate a clinical trial for tecarfarin in End-Stage Kidney Disease patients transitioning to dialysis.

Cadrenal Therapeutics announced plans to initiate a clinical trial for its lead drug candidate, tecarfarin, in patients with end-stage kidney disease transitioning to dialysis, with enrollment starting later this year.

Cadrenal Therapeutics, Inc. announced the resignation of director Robert Lisicki and set the date for its 2025 annual meeting of stockholders, along with revised deadlines for stockholder proposals.

Cadrenal Therapeutics announced its first-quarter 2025 financial results, highlighting progress in tecarfarin development and a collaboration with Abbott.

Cadrenal Therapeutics announced the filing of a prospectus supplement for an at-the-market offering of up to $2.17 million shares of its common stock.

Cadrenal Therapeutics reports its full year 2024 results, highlighting a collaboration with Abbott and progress in the clinical development of tecarfarin.

Cadrenal Therapeutics and Abbott have entered into a collaboration agreement to support the pivotal study of Tecarfarin in patients with HeartMate 3 LVADs, aiming to improve anticoagulation and hemocompatibility.

Cadrenal Therapeutics appoints James J. Ferguson as Chief Medical Officer, replacing Douglas Losordo, to lead the late-stage clinical development of tecarfarin and explore new business opportunities.

Cadrenal Therapeutics announced a corporate update, including progress on its tecarfarin clinical trial, recent financing, and third-quarter financial results.